)
Visual
test
Immutep
Immutep (IMM) investor relations material
Immutep Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary29 Jan, 2026
Executive summary
Entered strategic collaboration with Dr. Reddy's for efti commercialization outside North America, Europe, Japan, and Greater China, receiving ~A$30 million upfront and eligibility for up to ~A$528 million in milestones plus royalties.
Strong operational progress in TACTI-004 (KEYNOTE-F91) Phase III trial for 1L NSCLC, with futility analysis on track for Q1 CY2026.
Positive clinical data across multiple trials, including INSIGHT-003 (NSCLC), EFTISARC-NEO (soft tissue sarcoma), and AIPAC-003 (metastatic breast cancer).
IMP761 Phase I trial in autoimmune diseases showed dose-dependent immunosuppressive effects and favorable safety.
Received A$4.6 million R&D tax incentive from the French government.
Financial highlights
Cash, cash equivalents, and term deposits totaled A$99.1 million as of 31 December 2025; pro-forma balance of A$129.3 million after Dr. Reddy's upfront payment.
Net cash used in operating activities for the quarter was A$9.4 million, down from A$19.0 million in Q1 FY26.
Cash used in R&D activities was A$9.9 million, compared to A$15.8 million in the previous quarter.
Payments to related parties totaled A$474k for the quarter.
Cash reach extended well into Q2 CY2027, excluding future milestone payments.
Outlook and guidance
Cash position expected to fund operations well into Q2 CY2027.
Additional updates on IMP761 Phase I trial anticipated in H1 CY2026.
TACTI-004 futility analysis expected in Q1 CY2026; 50% patient enrollment target anticipated soon.
What does the A$30M vendor payment deferral signify?
How does 30mg efti dose impact TACTI-004 trial?
Why is INSIGHT-003's ORR in low PD-L1 significant?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 5 FebAPOLLOTYRE
Record revenue, profit growth, major expansion, and improved financial metrics in Q3 FY26. - 5 FebSHEL
$18.5B earnings, $26.1B free cash flow, and $22B+ returned to shareholders in 2025. - 5 FebQGEN
2025 results surpassed guidance; 2026 targets strong growth and margin expansion. - 5 FebBIXT
Polysaccharide antivirals blocking galectin show rapid, broad efficacy and near-term commercialization. - 5 FebEZPW
Net income up 43% and revenue up 19% as acquisitions expanded the store footprint. - 5 FebMTRX
Revenue up 12%, net loss narrows, backlog at $1.1B, FY2026 guidance reaffirmed. - 5 FebMET
Adjusted EPS up 10%, 16% ROE, and record AUM after major acquisition. - 5 FebBSANTANDER
Net income up 23% YoY, ROE 23.5%, efficiency 36%, with strong digital and fee growth. - 5 FebIDCC
Record 2025 results, strong licensing, and robust 2026 outlook with continued profitability. - 5 FebLADR
Q4 2025 distributable earnings hit $21.4M, with investment-grade status and strong loan growth.
Immutep
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Immutep Limited is a clinical-stage biotechnology company, recognized for its pioneering work in developing novel immunotherapy for cancer and autoimmune diseases. The company's research and development efforts are centered on Lymphocyte Activation Gene-3 (LAG-3), a crucial cell surface molecule that plays a significant role in regulating the immune system. Immutep's portfolio includes a range of innovative immunotherapies designed to either stimulate or suppress the immune system to combat cancer or autoimmune diseases. The company is headquartered in Sydney, Australia, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage